Figure 1

A. Establishment of the HA(QH)-mediated transduction assay and optimization of the HA(QH)-mediated transduction by neuraminidase treatment. The HA(QH)/HIV, VSV-G/HIV and HIV alone (no Env) pseudovirions were generated in 293T producer cells as described in Materials and Methods. These virions were separately incubated with the target cells (293T, HeLa, QT6, and DF-1), and the luciferase activity of each infected cell line, represented as log (relative luciferase units, or RLUs), was determined 48 h post-infection. HIV vector (no Env), background controls, VSV-G/HIV, positive controls. Values are means of triplicate samples ± SD. B. The HA(QH) plasmid were first co-transfected with the HIV vector to 293T producer cells, and the transfected cells were treated with a commercial neuraminidase at various concentrations (0, 5, 10, 20, 50, 100, and 200 units) at 26 h and 46 h post-transfection. The generated pseudovirions were collected at 48 h post-transfection and used to challenge the target cells (293T and A549), and the luciferase activities of the infected cells were determined 48 h post-infection. HIV vector (no EnV), background controls, VSV-G/HIV, positive controls. Values are means of triplicate samples ± SD.